Pfizer launches a gene therapy study for Duchenne MD; Amgen, NEA back real-world drug data software company – Endpoints News
Endpoints News |
Pfizer launches a gene therapy study for Duchenne MD; Amgen, NEA back real-world drug data software company
Endpoints News Pfizer has launched its closely-watched study of a new “mini-dystrophin” gene therapy for Duchenne muscular dystrophy. Duke's Edward Smith dosed the first boy on March 22. And data are expected in H1 of next year, after investigators get a chance to … Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid |
